Spyre Therapeutics, Inc.

SYREReported to SECin USCIK 0001636282Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 46. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 46
Form 4 lines at Spyre Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
King-Jones HeidySee RemarksOption exercisenothing paid400 sharesSep 3, 2026King-Jones HeidySee Remarksnothing paidExercise · Sep 3Option exercise400Sep 3, 2026
King-Jones HeidySee RemarksOption exercisenothing paid27,999 sharesSep 3, 2026King-Jones HeidySee Remarksnothing paidExercise · Sep 3Option exercise27,999Sep 3, 2026
King-Jones HeidySee RemarksOpen-market sell$36,000400 sharesSep 3, 2026King-Jones HeidySee Remarks$36,000Sell · Sep 3Open-market sell400Sep 3, 2026
King-Jones HeidySee RemarksOption exercise$5,800400 sharesSep 3, 2026King-Jones HeidySee Remarks$5,800Exercise · Sep 3Option exercise400Sep 3, 2026
King-Jones HeidySee RemarksOpen-market sell$35,752400 sharesSep 3, 2026King-Jones HeidySee Remarks$35,752Sell · Sep 3Open-market sell400Sep 3, 2026